Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is The Downturn A ‘Darwinian Moment’ For Biotech? The View From The Frontline

Cutbacks And Threat Of Closure Hitting Small To Medium Biotechs

Executive Summary

After the boom of 2020 and 2021, the biotech sector is experiencing one of the deepest and longest downturns but there are hopes that catalysts could soon revive confidence.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: will biotech overcome its slump?; Sanofi on the future of vaccines; J&J’s M&A ambitions; interview with a Korean immuno-oncology challenger; and a setback for the IL-2 approach in oncology.

As Biotech M&A Activity Gingerly Rises, Regeneron Makes Moves On Checkmate

Regeneron hopes to bolster its immuno-oncology pipeline with the acquisition of Checkmate, which joins a spate of similar deals suggesting renewed interest in biotech investment despite an industry-wide slowdown.

Orchard and Zealand Join Growing List Of Biotechs On The Ropes

Orchard and Zealand are the latest European players to succumb to a financial pinch in the biotech sector, streamlining their pipelines and laying off staff to save on expenses. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC146259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel